Grant Award Details
A phase 1 trial of Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
Grant Application Details
- Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
Therapeutic Candidate or Device
CNS10-NPC-GDNF - a neural progenitor cell secreting GDNF
This therapy will replace damaged astrocytes. The new astrocytes will release paracrine factors. As the cells have been modified to release GDNF they will also provide this factor to dying motor neurons.
Unmet Medical Need
There is no treatment or cure for ALS. Thus there is a huge unmet medical need.
Phase 1/2a clinical trial
Major Proposed Activities
Assess clinical safety of the therapeutic product
ALS is a devastating disease and there are over 6,000 cases in CA. If this treatment works it will provide one of the only ways to slow down motor neuron disease progression. This illness costs the state of California millions of dollars in healthcare costs and immense suffering to those Californians affected by the disease.